Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/1999
11/09/1999CA2004239C Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
11/04/1999WO1999055335A1 Substituted tricyclic pyrazole derivatives with protein kinase activity
11/04/1999WO1999055330A1 Ccr-3 receptor antagonists
11/04/1999WO1999055324A1 Ccr-3 receptor antagonists
11/04/1999WO1999055321A1 Compounds and methods for treating mitochondria-associated diseases
11/04/1999WO1999055304A1 Methods and compositions for stabilizing acetylcholine compositions
11/04/1999CA2329821A1 Ccr-3 receptor antagonists
11/04/1999CA2329777A1 Ccr-3 receptor antagonists
11/04/1999CA2329709A1 Compounds and methods for treating mitochondria-associated diseases
11/03/1999EP0952974A1 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
11/03/1999EP0535200B1 Procedure for the purification of hyaluronic acid and fraction of pure hyaluronic acid for ophthalmic use
11/03/1999CN1234039A 3-mercaptoacetylamino-1,5-subsd. 2-oxo-azepon derivatives useful as inhibitor of metrix metalloproteinase
11/03/1999CN1234031A Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the prodn. of tumor necrosis factor (TNF)
11/03/1999CN1234026A Piperazino derivatives as neurokinin antagonists
11/02/1999USRE36375 Treatment of Alzheimer's disease using azacyclic compounds
11/02/1999US5977359 Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
11/02/1999US5977337 The nucleic acid molecule may be used in the diagnosis of infection.
11/02/1999US5977129 Alzheimer's disease
10/1999
10/28/1999WO1999054333A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
10/28/1999WO1999054310A2 New substituted amides, their production and their use
10/28/1999WO1999054304A1 Heterocyclically substituted amides, their production and their use
10/28/1999WO1999054294A1 New substituted amides, their production and their use
10/28/1999WO1999054284A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999WO1999054280A1 Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
10/28/1999WO1999053932A1 Streptococcus preparation
10/28/1999WO1999053899A1 Medicinal compositions for application to mucosa
10/28/1999CA2328435A1 New substituted amides, their production and their use
10/28/1999CA2328413A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999CA2325805A1 Streptococcus preparation
10/27/1999EP0951295A1 Methods and compositions useful for inhibition of angiogenesis
10/27/1999EP0951285A1 Inhibitors of farnesyl-protein transferase
10/27/1999CN1233181A Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
10/27/1999CN1233180A Treatment of the common cold or allergic rhinitis
10/27/1999CN1233179A Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
10/27/1999CN1233173A Therapeutic methods and compositions involving isoflavones
10/26/1999US5973009 Antioxidant and cytoprotecting activity
10/26/1999US5972977 Ophthalmic pharmaceutical compositions comprising a nitrone compound and methods for treating ocular inflammation using such compositions
10/26/1999US5972972 Pyrazoles as human non-pancreatic secretory phospholipase A2 inhibitors
10/26/1999US5972940 Arginine analogues having nitric oxide synthase inhibitor activity
10/26/1999US5972896 Antiangiogenic peptides and methods for inhibiting angiogenesis
10/26/1999US5972652 Polynucleotides encoding secreted proteins
10/26/1999US5972651 Polynucleotides and polypeptides of the fifty-four homologue family, (ffh); vectors and transformed host cells; ffh are components of protein secretory apparatus and their inhibition of function is deleterious to bacteria cells
10/26/1999CA2183320C Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
10/21/1999WO1999053060A2 Glaucoma therapeutics and diagnostics based on a novel human transcription factor
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052903A1 Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
10/21/1999WO1999052896A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052868A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052559A1 OPHTHALMIC COMPOSITION COMPRISING A β-BLOCKER
10/21/1999WO1999052555A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors
10/21/1999WO1999052554A1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
10/21/1999WO1999052514A2 Pharmaceutical composition and combination preparation for immunosuppressive therapy
10/21/1999WO1999045920A3 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
10/21/1999WO1999044624A3 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
10/21/1999DE19818614A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817459A1 New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999CA2328211A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999CA2328075A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors
10/21/1999CA2327431A1 Pharmaceutical composition
10/21/1999CA2326665A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999CA2324480A1 Glaucoma therapeutics and diagnostics based on a novel human transcription factor
10/20/1999EP0950413A2 Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy
10/20/1999EP0950101A1 Secreted proteins and polynucleotides encoding them
10/20/1999EP0950065A1 Peptide as diagnostic and therapeutic agent for autoimmune diseases
10/20/1999EP0950047A1 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
10/20/1999EP0950046A1 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
10/20/1999EP0949904A1 Pharmaceutical compositions
10/20/1999EP0740655B1 Metalloproteinase inhibitors
10/20/1999EP0673250B1 Ophthalmic compositions comprising emedastine and their use for treating allergic conjunctivitis
10/20/1999EP0643581B1 Ocular androgen therapy in sjögren's syndrome
10/20/1999CN1232501A Modified TIE-2 -receptor ligands
10/20/1999CN1232457A 1,4-heterocyclic metalloprotease inhibitors
10/20/1999CN1232451A Substd. cyclic amine metalloprotease inhibitors
10/20/1999CN1232397A Use of H+, K+-ATPase inhibitor in treatment of nasal polyps
10/20/1999CN1045777C Tetracyclic derivs. process of preparation and use
10/20/1999CN1045768C Angiotension II antagonists compounds, preparing method and use thereof
10/19/1999US5969093 Secreted proteins
10/19/1999US5968949 Substituted hydroisoquinoline derivatives and their use as pharmaceuticals
10/19/1999US5968920 Increase glutathione peroxidase activity for reducing levels of peroxides in cells or tissues
10/19/1999US5968824 Administering agent which modulates biochemical pathway in which products of opioid peptide precursor genes participate; antitumor agents; prevention of opacity of intraocular lens after cataract surgery
10/19/1999US5968777 DNA encoding seryl t-RNA synthetase
10/14/1999WO1999051605A1 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR
10/14/1999WO1999051273A1 Gelling ophthalmic compositions containing xanthan gum
10/14/1999WO1999051230A1 Method for stabilizing pharmaceutical compositions by special use of an antioxidant
10/14/1999WO1999051204A1 Ocular irrigating solution
10/14/1999DE19807426A1 Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs A method for the treatment of diseases or disorders of the inner ear
10/14/1999CA2326522A1 Pyrrolo¬1,2-a|pyrazine spla2 inhibitor
10/13/1999EP0949245A1 Process for alkylating hindered sulfonamides
10/13/1999EP0948605A1 Truncated platelet-activating factor acetylhydrolase
10/13/1999EP0948520A1 Tissue specific expression of retinoblastoma protein
10/13/1999EP0948500A1 Cyclic organoselenium compounds, their preparation and their uses
10/13/1999EP0948495A1 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
10/13/1999EP0948478A1 ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO 1,2-g]-CHROM-3-ENE, BENZO 1,2-g]-THIOCHROM-3-ENE AND BENZO 1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
10/13/1999EP0948357A1 Use of low molecular weight amino alcohols in ophthalmic compositions
10/13/1999EP0948349A1 Treatment of inner ear hair cells
10/13/1999EP0948333A1 Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
10/13/1999EP0948329A1 Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts
10/13/1999EP0948327A1 Antidiabetic agents
1 ... 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 ... 531